Señalización PI3K / Akt / mTOR
Los inhibidores de la señalización PI3K/Akt/mTOR son compuestos que se dirigen a las vías de la fosfoinositida 3-cinasa (PI3K), la cinasa Akt y el blanco de la rapamicina en mamíferos (mTOR). Estas vías son reguladores críticos del crecimiento celular, la supervivencia, el metabolismo y la autofagia, lo que las convierte en objetivos clave en la investigación del cáncer y los trastornos metabólicos. Inhibir estas vías puede ayudar a controlar el crecimiento y la proliferación tumoral, ofreciendo potenciales estrategias terapéuticas para varios tipos de cáncer y otras enfermedades caracterizadas por una señalización celular desregulada. En CymitQuimica, ofrecemos una amplia selección de inhibidores de alta calidad de PI3K/Akt/mTOR para apoyar su investigación en oncología, señalización celular y enfermedades metabólicas.
Subcategorías de "Señalización PI3K / Akt / mTOR"
- AMPK(158 productos)
- ATM / ATR(71 productos)
- ADN-PK(51 productos)
- EGFR(572 productos)
- MELK(7 productos)
- PDK(9 productos)
- PI3K(242 productos)
- Quinasa S6(9 productos)
- gsk-3(112 productos)
- mTOR(144 productos)
Mostrar 2 subcategorías más
Se han encontrado 1038 productos de "Señalización PI3K / Akt / mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
DNA-PK-IN-1
CAS:<p>DNA-PK-IN-1 is a potent inhibitor of DNA-PK. DNA-PK-IN-1 has potential for cancer disease research.</p>Fórmula:C23H26N8O2Forma y color:SolidPeso molecular:446.5WR23
CAS:<p>WR23 is a piperidinylquinoxaline derivative and a phosphoinositide 3-kinase α (PI3Kα) inhibitor.</p>Fórmula:C19H18BrN3O3SPureza:98%Forma y color:SolidPeso molecular:448.33LTURM-36
CAS:<p>LTURM-36 is a novel inhibitor of PI 3-kinase delta.</p>Fórmula:C22H18N2O3Pureza:98%Forma y color:SolidPeso molecular:358.39ZDWX-25
CAS:<p>ZDWX-25, a strong GSK-3β & DYRK1A inhibitor, kills SH-SY5Y/HL-7702 cells, may aid Alzheimer's research; IC50: 71 nM for GSK-3β.</p>Fórmula:C17H15N3O3Forma y color:SolidPeso molecular:309.32MIPS-9922
CAS:<p>MIPS-9922: potent PI3Kβ inhibitor; prevents αIIbβ3 activation, platelet adhesion, and ADP-triggered aggregation.</p>Fórmula:C28H31F2N9O2Pureza:98%Forma y color:SolidPeso molecular:563.6NSC81111
CAS:<p>NSC81111 shows anticaner effects which is a potent and orally active inhibitor of EGFR-TK (IC50 = 0.15 nM) [1].</p>Fórmula:C19H16O4Forma y color:SolidPeso molecular:308.33Limertinib
CAS:<p>Limertinib (ASK120067) is a EGFR tyrosine kinase inhibitor targeting EGFR T790M, applicable for the study of non-small cell lung cancer.</p>Fórmula:C29H32ClN7O2Pureza:97.44%Forma y color:SolidPeso molecular:546.06GNE-293
CAS:<p>GNE-293 is a potent and selective PI3Kδ inhibitor.</p>Fórmula:C28H36N8O4SPureza:98%Forma y color:SolidPeso molecular:580.7PI-540
CAS:<p>PI-540 is a potent and selective inhibitor of class 1A phosphatidylinositide 3-kinases (PI3K).</p>Fórmula:C22H27N5O2SForma y color:SolidPeso molecular:425.55DNA-PK-IN-3
CAS:<p>DNA-PK-IN-3 is a potent DNA-PK inhibitor, enhancing radio/chemotherapy and reducing tumors with limited side effects.</p>Fórmula:C19H19N9OForma y color:SolidPeso molecular:389.41PI3K-IN-6
CAS:<p>PI3K-IN-6 is an oral active and highly selective inhibitor of phosphoinositide 3-kinase (PI3K) β/δ(IC50 values of 7.8 nM/5.3 nM , respectively).</p>Fórmula:C17H14Cl2FN9OPureza:98%Forma y color:SolidPeso molecular:450.26PI3Kδ/γ-IN-2
CAS:<p>PI3Kδ/γ-IN-2 is a potent, orally bioavailable dual inhibitor of PI3Kδ (IC50: 1 nM) and PI3Kγ (IC50: 4.3 nM) with potential for use in anti-B-cell malignancy</p>Fórmula:C25H21ClN8OForma y color:SolidPeso molecular:484.94GLPG3970
CAS:<p>GLPG3970, a pioneering inhibitor of SIK2/SIK3, is utilized in the investigation of inflammation and autoimmune diseases.</p>Fórmula:C25H27F3N4O4Pureza:99.60% - >99.99%Forma y color:SolidPeso molecular:504.5EGFR-IN-68
CAS:<p>EGFR-IN-68, an EGFR inhibitor, has an IC50 of 0.33 μM and shows significant anticancer effects.</p>Fórmula:C24H22N2OForma y color:SolidPeso molecular:354.44EAI001
CAS:<p>EAI001 is a potent and selective mutant epidermal growth factor receptor (EGFR) variant inhibitor that inhibits EGFRL858R/T790M with an IC50 value of 24 nM.</p>Fórmula:C19H15N3O2SPureza:>99.99%Forma y color:SolidPeso molecular:349.41PI3Kγ inhibitor 4
CAS:<p>PI3Kγ inhibitor 4 is a selective, potent, orally active PI3Kγ inhibitor (IC50: 40 nM).</p>Fórmula:C20H24N4O4SForma y color:SolidPeso molecular:416.49Nimotuzumab
CAS:<p>Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).</p>Pureza:95.00% - 98.5% (SDS-PAGE); 96.4% (SEC-HPLC)Forma y color:LiquidMRT80
CAS:<p>MRT80 is an inhibitor of GSK-3 in vitro. MRT80 de-stabilizes MDM2 and stabilizes p53 protein and E2F-1.</p>Fórmula:C15H15N5OPureza:98%Forma y color:SolidPeso molecular:281.31mTOR inhibitor-2
CAS:<p>mTOR inhibitor-2 is an inhibitor of selective and oral mTOR (IC50 of 7 nM).</p>Fórmula:C23H21N7OPureza:98%Forma y color:SolidPeso molecular:411.46SDZ281-977
CAS:<p>SDZ 281-977 is a derivative of Lavendustin A which is the EGF receptor tyrosine kinase inhibitor.</p>Fórmula:C18H20O5Pureza:99.64%Forma y color:SolidPeso molecular:316.35(E/Z)-CP-724714
CAS:<p>(E/Z)-CP-724714, comprising racemic mixtures of (E)-CP-724714 and (Z)-CP-724714 isomers, is a potent, selective, and orally active inhibitor of ErbB2 (HER2)[1].</p>Fórmula:C27H27N5O3Pureza:98%Forma y color:SolidPeso molecular:469.54AG-183
CAS:<p>(Z)-Tyrphostin A51, a Z-isomer of Lanoconazole A51, is a strong PTK inhibitor blocking [3 H]taurine release and tyrosyl phosphorylation.</p>Fórmula:C13H8N4O3Forma y color:Brown SolidPeso molecular:268.23PI3Kα-IN-13
CAS:<p>PI3Kα-IN-13 (Compound 18a), a PI3Kα inhibitor with an IC50 of 2.5 nM, effectively induces apoptosis and hampers the proliferation of various cancer cell lines,</p>Fórmula:C21H19N5O3Pureza:98%Forma y color:SolidPeso molecular:389.41Nemiralisib
CAS:<p>Nemiralisib (GSK-2269557) is an oral PI3Kδ inhibitor (pKi 9.9) for treating respiratory diseases like COPD.</p>Fórmula:C26H28N6OPureza:99.91%Forma y color:SolidPeso molecular:440.54PI4KIII β inhibitor 3
CAS:<p>PI4KIII beta inhibitor 3 is a novel and high effective inhibitor of PI4KIIIβ (IC50 of 5.7 nM).</p>Fórmula:C22H22N8OSPureza:98%Forma y color:SolidPeso molecular:446.53TGX-155
CAS:<p>TGX-155 is a selective PI3K inhibitor.</p>Fórmula:C20H19FN2O3Pureza:98%Forma y color:SolidPeso molecular:354.37FT-1518
CAS:<p>FT-1518 is an orally available, selective and potent mTORC1 and mTORC2 inhibitor with anticancer and antitumor activity for cancer research.</p>Fórmula:C20H26N8OPureza:98.34% - 98.80%Forma y color:SolidPeso molecular:394.47Tarlox-TKI
CAS:<p>Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, which has antitumor activity.</p>Fórmula:C19H18BrClN6OPureza:97.03%Forma y color:SolidPeso molecular:461.74AZD3458
CAS:<p>AZD3458 is a potent and remarkably selective inhibitor of PI3Kγ (PI3Kγ, PI3Kα, PI3Kβ, and PI3Kδ with pIC50s of 9.1, 5.1, <4.5, and 6.5 , respectively).</p>Fórmula:C20H23N3O4S2Forma y color:SolidPeso molecular:433.54RV-1729
CAS:<p>RV-1729, a phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor, is used potentially for the treatment of asthma.</p>Fórmula:C39H39ClN8O5Forma y color:SolidPeso molecular:735.23BKI-1369
CAS:<p>BKI-1369 is a bumped kinase inhibitor. BKI-1369 increases hERG-inhibitory activity (IC50:1.52 μM).</p>Fórmula:C23H27N7OForma y color:SolidPeso molecular:417.51RTC-5
CAS:<p>RTC-5 (TRC-382) is a phenothiazine compound that has been specifically enhanced for its potent anti-cancer properties.</p>Fórmula:C24H22ClF3N2O3SPureza:98.14%Forma y color:SolidPeso molecular:510.96CAL-130 Hydrochloride
CAS:<p>CAL-130 Hydrochloride is a PI3Kδ and PI3Kγ inhibitor (IC50s: 1.3 and 6.1 nM).</p>Fórmula:C23H23ClN8OForma y color:SolidPeso molecular:462.94EGFR-IN-50
CAS:<p>EGFR-IN-50, a potent EGFR blocker, hinders L858R mutation; GI50: 8 nM for TEL-EGFR-L858R, 6.03 μM for T790M-L858R; curbs cancer cell growth.</p>Fórmula:C24H26BrN3O4S2Forma y color:SolidPeso molecular:564.51NSC114126
CAS:<p>NSC114126 is a potent, oral EGFR-TK inhibitor with strong antiproliferative effects, promising for cancer research.</p>Fórmula:C22H20O4Forma y color:SolidPeso molecular:348.39JBJ-04-125-02
CAS:<p>JBJ-04-125-02: Oral EGFR inhibitor, targets EGFRL858R/T790M with 0.26 nM IC50, halts cancer growth, anti-tumor.</p>Fórmula:C29H26FN5O3SPureza:98%Forma y color:SolidPeso molecular:543.61PIKfyve-IN-2
CAS:<p>PIKfyve-IN-2 is a potent inhibitor of the PIKfyve kinase, with potential applications in cancer and autoimmune disorder research [1].</p>Fórmula:C22H22N8OForma y color:SolidPeso molecular:414.46BRD3731
CAS:<p>BRD3731 selectively inhibits GSK3β with IC50 of 15 nM; it's promising for PTSD, psychiatric issues, diabetes, and neurodegeneration.</p>Fórmula:C24H31N3OForma y color:SolidPeso molecular:377.523F8
CAS:<p>3F8 is a selective GSK-3β inhibitor that can be used as a new tool and potential therapeutic candidate compound for GSK3-related diseases, and can be used in</p>Fórmula:C15H14N2O4Pureza:98.14% - 98.25%Forma y color:SolidPeso molecular:286.28Epertinib
CAS:<p>Epertinib is a reversible and selective tyrosine kinase inhibitor of EGFR, HER2, and HER4 (IC50s: 1.48 nM, 7.15 nM, and 2.49 nM).</p>Fórmula:C30H27ClFN5O3Pureza:98%Forma y color:SolidPeso molecular:560.02EGFR-IN-64
CAS:<p>EGFR-IN-64 inhibits EGFR with 0.33 μM IC50, showing promising anticancer properties.</p>Fórmula:C20H21N3O3Forma y color:SolidPeso molecular:351.4(R)-PS210
CAS:<p>(R)-PS210, the R enantiomer of PS210 is a substrate-selective allosteric PDK1 activator with an (AC50 of 1.8 μM).</p>Fórmula:C19H15F3O5Forma y color:SolidPeso molecular:380.31GW 583340 dihydrochloride
CAS:<p>GW 583340 dihydrochloride is a potent and orally available dual EGFR/ErbB2 inhibitor and inhibits 80% of tumor growth in a mouse xenograft mode.</p>Fórmula:C28H27Cl3FN5O3S2Pureza:98.80%Forma y color:SolidPeso molecular:671.03FD2056
CAS:<p>FD2056 is a potent, orally active PI3K inhibitor, with IC50 values of 0.30, 0.80, 1.10, and 0.42 nM against PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ, respectively.</p>Fórmula:C23H17ClN6O2SPureza:98%Forma y color:SolidPeso molecular:476.94EGFR-IN-89
CAS:<p>EGFR-IN-89 (compound 13k) is a fourth-generation inhibitor selectively targeting EGFR mutations, exhibiting potent activity with an IC50 of 10.1 nM against</p>Fórmula:C26H31FN8O2SPureza:98%Forma y color:SolidPeso molecular:538.64AMPK activator 12
CAS:<p>AMPK activator 12 is an AMPK activator and GDF15 inducer that elevates the expression level of GDF15 protein for cancer research.</p>Fórmula:C23H24BrNO2Pureza:99.55%Forma y color:SolidPeso molecular:426.35PI5P4Ks-IN-1
CAS:<p>PI5P4Ks-IN-1 (compound 7) is an active compound which engages PI5P4Kγ[1].</p>Fórmula:C20H17N3SForma y color:SolidPeso molecular:331.43Antiproliferative agent-34
CAS:<p>Antiproliferative Agent-34 (Compound A14), a multitarget kinase inhibitor, demonstrates IC50 values of 177 nM for EGFR L858R/T790M and 1567 nM for EGFR WT.</p>Fórmula:C27H27N7O5Pureza:98%Forma y color:SolidPeso molecular:529.55PIMPC
CAS:<p>PIMPC, a compound endowed with antioxidant and metal-chelating properties, acts as a novel inhibitor of glycogen synthase kinase 3 (GSK-3), and exhibits</p>Fórmula:C21H19N5OPureza:98%Forma y color:SolidPeso molecular:357.41PI3Kγ inhibitor 7
CAS:<p>PI3Kγ Inhibitor 7 (compound 2) is a potent, orally active agent that selectively inhibits PI3Kγ with an IC50 of 3.42 nM and demonstrates antitumor activity [1].</p>Fórmula:C31H25N9O2Pureza:98%Forma y color:SolidPeso molecular:555.59
